Matilde Lleonart Pajarin I am group leader of "Biomedical Research in Cancer Stem Cells" at VHIR. I arrived at VHIR 21 years ago after having worked in different prestigious international research centers: World Health Organization (WHO) at the International Agency for Research on Cancer (IARC) (Lyon, France), the Wolfson Institute for Biomedical Research (WIBR) in London and the Queen´s Mary University of London. Instituciones de las que forman parte Jefe de grupo Cáncer de cabeza y cuello: Investigación biomédica en células madre tumorales Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Email Matilde Lleonart Pajarin LinkedIn Twitter Orcid Email Instituciones de las que forman parte Jefe de grupo Cáncer de cabeza y cuello: Investigación biomédica en células madre tumorales Vall Hebron Institut de Recerca I am group leader of "Biomedical Research in Cancer Stem Cells" at VHIR. I arrived at VHIR 21 years ago after having worked in different prestigious international research centers: World Health Organization (WHO) at the International Agency for Research on Cancer (IARC) (Lyon, France), the Wolfson Institute for Biomedical Research (WIBR) in London and the Queen´s Mary University of London.
My Research Group was recognized as an Emerging Research Group in 2009 by the Generalitat de Catalunya and later in 2014 as a Consolidated Research Group. Throughout my career I have been involved in cancer research from a more molecular point of view correlating key mutations in oncogenes and tumor suppressor genes with anatomical, pathological and clinical features of patients' tumors and also through cell culture studies to determine important key cell signaling pathways in tumorigenesis. Currently, the main lines of research of my Research Group focus on the identification and characterization of biological mechanisms in resistant cancer cells, including cancer stem cells, to unravel the pathways responsible for their resistance in breast, lung and head and neck cancer models. In addition, we are particularly focused on identifying molecular targets in resistant cancer cells and cancer stem cells affecting particularly aggressive tumors. The aim is to attack them pharmacologically in order to propose new cancer therapies: new drugs and/or drug combinations to combat resistant tumors in mouse models.
Proyectos Therapeutical approaches against chemoresistant cancers IP: Matilde Lleonart Pajarin Colaboradores: Yoelsis Garcia Mayea, Fco. Xavier De la Cruz Montserrat, Juan Lorente Guerrero, Sergio Benavente Norza, Therapeutical approaches against chemoresistant cancers, Marina Bataller Fernández, Therapeutical approaches against chemoresistant cancers, Therapeutical approaches against chemoresistant cancers Entidad financiadora: Agència Gestió Ajuts Universitaris i de Recerca Financiación: 0.01 Referencia: 2021 SGR 01205 Duración: 01/01/2022 - 30/06/2025 Ayudas Margarita Salas IP: Matilde Lleonart Pajarin Colaboradores: Yoelsis Garcia Mayea, Ayudas Margarita Salas Entidad financiadora: Ministerio de Universidades Financiación: 0.01 Referencia: MIU/M_SALAS/2021/GARCIA_UB Duración: 01/04/2022 - 31/03/2022 Novel terapéutic approaches against COVID-19 IP: Matilde Lleonart Pajarin Colaboradores: Marina Bataller Fernández, Novel terapéutic approaches against COVID-19, Yoelsis Garcia Mayea Entidad financiadora: Fundació La Marató de TV3 Financiación: 161875 Referencia: 202116 Duración: 23/09/2021 - 22/09/2024 New therapeutic approaches in head and neck cancer IP: Matilde Lleonart Pajarin Colaboradores: Irene Braña Garcia, Yoelsis Garcia Mayea, Jordi Temprana Salvador, Angel García Jiménez, Sergio Benavente Norza, Josep Castellví Vives, Laia Josa Culleré, Marina Bataller Fernández Entidad financiadora: Instituto de Salud Carlos III Financiación: 183920 Referencia: PI20/00556 Duración: 01/01/2021 - 30/06/2025 Paginación Primera página « Página anterior ‹ Página 1 Página 2 Página actual 3 Página 4 Página 5 … Siguiente página › Última página »
